|
Originally published In Press as doi:10.1074/jbc.M203185200 on September 16, 2002
J. Biol. Chem., Vol. 277, Issue 48, 45962-45968, November 29, 2002
trans-Sialidase from Trypanosoma cruzi
Binds Host T-lymphocytes in a Lectin Manner*
Adriane R.
Todeschini ,
Murielle F.
Girard§¶,
Jean-Michel
Wieruszeski ,
Marise P.
Nunes§,
George A.
DosReis§**,
Lúcia
Mendonça-Previato§** , and
José O.
Previato§
From the Departamento de Bioquímica,
Instituto de Biologia, 20551-013 Universidade do Estado do Rio
de Janeiro, Brasil, § Instituto de Biofísica Carlos
Chagas Filho, Centro de Ciências da Saúde - Bloco G,
Universidade Federal do Rio de Janeiro, 21 944970, Cidade
Universitária, Ilha do Fundão, Rio de Janeiro, Brasil, and
Laboratoire de RMN Synthese, Structure et Fonction des
Biomolecules, Institut Pasteur, 59019 Lille, France
Received for publication, April 3, 2002, and in revised form, August 16, 2002
 |
ABSTRACT |
Trypanosoma cruzi, the protozoan
parasite responsible for Chagas' disease, expresses on its
surface an uncommon membrane-bound sialidase, known as
trans-sialidase. trans-Sialidase is the product of a multigene family encoding both active and inactive proteins. We
report here that an inactive mutant of trans-sialidase
physically interacts with CD4+ T cells. Using a combination
of flow cytometry and immunoprecipitation techniques, we identified the
sialomucin CD43 as a counterreceptor for trans-sialidase on
CD4+ T cells. Using biochemical, immunological, and
spectroscopic approaches, we demonstrated that the inactive
trans-sialidase is a sialic acid-binding protein displaying
the same specificity required by active trans-sialidase.
Taken together, these results suggest that inactive members of the
trans-sialidase family can physically interact with sialic
acid-containing molecules on host cells and could play a role in
host cell/T. cruzi interaction.
 |
INTRODUCTION |
The surface of the protozoan parasite Trypanosoma
cruzi, the causative agent of Chagas' disease (American
Trypanosomiasis), displays a unique enzyme known as
trans-sialidase
(TS)1 (1, 2). TS is a
modified sialidase (3) sharing the catalytic mechanism (4) and the
active site architecture (5) with other known sialidases (6-8).
However, instead of releasing sialic acid, TS preferentially transfers
sialic acid from -galactopyranosyl ( Galp)-containing exogenous donor molecules to
terminal Galp-containing acceptors, attaching it in an
2-3 linkage configuration (9). T. cruzi TS belongs to a
large family of proteins (10, 11), and several other members of this
family, which lack enzymatic activity (11), are expressed. Comparison
of the deduced amino acid sequences shows that enzymatic activity
requires a Tyr at position 342, whereas inactive members contain a His
at the same position (11). The Tyr342 residue is involved
in the stabilization of the transition-state sialyl carbocation formed
during the hydrolysis reaction (4, 5). Indirect evidence suggests that
an enzymatically inactive recombinant TS acts as a lectin,
agglutinating desialylated erythrocytes (12). However, no direct
evidence for a Galp binding site or for its role in the
parasite host interaction has been established.
Trypomastigote-derived TS is anchored to the membrane through a
glycosylphosphatidylinositol anchor and is released to the extracellular medium during acute T. cruzi infection in
humans (13), thus acting distant from the parasite. Besides a role in
mammalian cell invasion (14), the soluble TS functions as a virulence
determinant molecule. Chuenkova and Pereira (15) demonstrated that
in vivo injection of minute amounts of purified native TS
increases subsequent parasitemia and mortality in T. cruzi-infected mice. As TS injection into severe combined
immunodeficiency mice did not affect parasitemia or mortality, it was
suggested that TS acts on the host adaptive immune response (15). It is well known that T lymphocytes bearing conventional  T cell
receptors are required for control of parasitemia and mortality in
murine infection by T. cruzi (16). Host
CD4+ T cells are also involved in the immunopathology of
T. cruzi infection, and their exacerbated function can lead
to mortality in susceptible hosts (17). Recently, we demonstrated that
both enzymatically active and inactive TS costimulated CD4+
T cell activation in vitro and in vivo and
blocked activation-induced cell death in CD4+ T cells from
T. cruzi-infected mice through CD43 engagement
(18). In the present work, we extended our studies and, using
CD43 / mice, we show that the major lymphocyte mucin
CD43 is the counterreceptor for the inactive TS on host
CD4+ T cells. We also employed NMR spectroscopy and
immunochemical approaches to investigate the nature of the CD43 epitope
that functions as ligand for TS, and we demonstrated that inactive TS
binds to sialic acid-containing molecules with the same specificity exhibited by active TS.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Most of the chemical products used were
from Sigma or Fisher. The following materials were obtained from other
sources: microtiter plates were from Nunc; protein G-Sepharose,
prepacked Ni2+-chelating HP HiTrap, Mono Q HR 10/10 and
Mono S HR 5/5 columns, and enhanced chemiluminescence (ECL) hyperfilm
were from Amersham Biosciences; biotin-conjugated polyacrylamide (PAA)
probes substituted with sialylated glycans ( 2-3-sialyllactose-PAA
( 2-3-SL-PAA), 2-6-sialyllactose-PAA, ( 2-6-SL-PAA),
NeuAc 2-3Gal 1-3(Fuc 1-4)-GlcNAc-PAA (SLeX-PAA)) were
from Glycotech; anti-rat Ig chain mAb MAR 18.5 was from Cedarlane
Laboratories; the sialic acid-dependent anti-CD43 mAb S7
(19), fluorescein isothiocyanate-labeled anti-CD43 mAb S7,
anti-CD16/CD32 mAb 2.4G2 (Fc block), phycoerythrin (PE)-conjugated streptavidin, horseradish peroxidase-conjugated anti-mouse IgG, and
peroxidase-conjugate streptavidin were from Pharmingen; serum-free Dulbecco's modified Eagle's medium was from Invitrogen.
Recombinant TS--
Recombinant active TS (rTS) and inactive TS
(irTS), containing the C-terminal repeats, were obtained from
Escherichia coli MC1061 electro-transformed with plasmids
containing either the wild-type TS insert, TSREP (11), or the
inactive mutant TS insert bearing a Tyr342 His
substitution, pTrcHisA (11). Bacteria were grown in supplemented Terrific broth in the presence of 100 µg/ml ampicillin. When the culture reached an A600 nm of 1.0, 30 mg/liter
isopropyl-1-thio- -D-galactopyranoside was added, and
incubation continued overnight. Bacteria were lysed at 4 °C in 20 mM Tris-HCl containing 2.0 mg/ml lysozyme, 2% Triton X-100, 0.1 µM phenylmethylsulfonyl fluoride, 5.0 µg/ml
leupeptin, 1.0 µg/ml trypsin inhibitor, and 0.1 µM
iodoacetamide. Both rTS and irTS containing a poly-His tag were
purified as described by Buschiazzo et al. (20) and modified
by Todeschini et al. (4) using Ni2+-chelating
chromatography on a HiTrap column and eluted with an imidazole gradient
(0-1 M). The eluates were dialyzed against 20 mM Tris-HCl, pH 7.6, further purified by ion exchange
chromatography on Mono Q and Mono S columns, applying a linear NaCl
gradient (0-1 M), and stored in 20 mM Tris-HCl
buffer, pH 7.6, at 4 °C until used. The homogeneity of proteins was
evaluated on 10% SDS-PAGE. For flow cytometry (FCM) and Western
blotting analyses, irTS was biotin-conjugated as described previously
(21).
rTS Activity Assay--
Enzyme activity was assayed by
incubating rTS preparations in 5 mM cacodylate buffer, pH
7.0, in the presence of 0.25 µmol of 2-3-sialyllactose
( 2-3-SL) and 0.25 µmol of
[D-glucose-1-14C]lactose (400,000 cpm) (4).
After incubation for 30 min at 37 °C, the reaction mixture was
diluted with 1 ml of water and applied to a column containing 1 ml of
Dowex 2X8 (acetate form) equilibrated with water. To remove the excess
of [D-glucose-1-14C]lactose, the column was
washed with 10 ml of water, and sialylated [D-glucose-1-14C]lactose was eluted with 3 ml
of 0.8 M ammonium acetate and quantitated by scintillation
counting (Beckman LS 6500). One unit was defined as the amount of rTS
required to catalyze the incorporation of 1 µmol of sialic acid into
lactose per minute.
Animals and T Lymphocytes--
BALB/c mice (male, aging 4-5
weeks) were obtained from Fundação Oswaldo Cruz, Rio de
Janeiro, Brasil; CD43 / and wild-type control mice (22)
were from Universidade Federal de São Paulo, São Paulo,
Brasil, animal facilities. All experiments were conducted according to
protocols approved by the Committee on Ethics and Regulations of Animal
Use of Instituto de Biofísica Carlos Chagas Filho, Universidade
Federal do Rio de Janeiro, Brasil.
Primary T cell-enriched suspensions were obtained by nylon-wool
filtration of fractionated splenocytes depleted of red cells by
treatment with Tris-buffered ammonium chloride (23). Purified CD4+ T cells were nylon-nonadherent cells treated with
anti-CD8 mAb for 30 min at 4 °C followed by anti-rat Ig chain mAb MAR 18.5 plus 10% rabbit complement for 45 min at
37 °C.
Immunoprecipitation and Western Blotting--
1 × 107 CD4+ T cells were lysed in PBS containing 1 mM phenylmethylsulfonyl fluoride, 5 µg/ml leupeptin, 0.1 µM iodoacetamide, 1 µg/ml trypsin inhibitor, and 0.1%
Triton X-100 for 1 h at 4 °C under vigorous shaking. After
pelleting (10,000 × g for 30 min), the supernatant was
precleared overnight at 4 °C with 100 µl of protein G-Sepharose
beads and centrifuged, and the supernatant was incubated with 3 µg of
anti-CD43 mAb S7 for 2 h at 4 °C, under shaking. Protein
G-Sepharose (50 µl) was added and incubated for 3 h. The beads
were separated by centrifugation, washed three times, and incubated
with SDS sample buffer for 5 min at 100 °C. The supernatant was run
on 10% SDS-PAGE and transferred to nitrocellulose membranes. Membranes
were blocked overnight with 2% bovine serum albumin in Tris-buffered
saline containing 0.2% Tween 20, incubated with anti-CD43 mAb S7 for
2 h followed by incubation with horseradish peroxidase-conjugated
anti-mouse IgG. The reaction was detected using enhanced
chemiluminescence (ECL) in Hyperfilm-ECL according to the
manufacturer's instructions. For irTS immunoprecipitation, streptavidin beads and biotin-conjugated irTS were used.
Desialylation and Resialylation of T Lymphocytes--
1 × 107 T cells were resuspended in serum-free Dulbecco's
modified Eagle's medium and incubated for 30 min at 37 °C
with 0.05 units of Clostridium perfringens (Type X)
sialidase in a total volume of 500 µl. Sialidase was removed by
washing three times with serum-free Dulbecco's modified Eagle's
medium. Desialylated T cells (5 × 106) were
resialylated by incubation with 0.05 units of recombinant rTS in the
presence of 1 mM 2-3-SL for 30 min at room temperature and washed as described above. Desialylated and resialylated T lymphocytes were resuspended in sorting buffer (10 mM PBS,
pH 7.4, containing 2% bovine serum albumin, 0.02% NaN3,
and 0.1 M lactose) incubated with biotin-conjugated irTS
for 30 min at 4 °C, washed, stained with PE-conjugated streptavidin,
and analyzed by FCM as described below.
FCM Analysis--
T cell-enriched suspension was incubated with
10 µg/ml Fc block for 5 min at 4 °C followed by addition of 10 µg/ml fluorescein isothiocyanate-labeled anti-CD43 mAb S7 or 10 µg/ml biotin-conjugated irTS for 30 min at 4 °C. The T cells were
then washed in sorting buffer, incubated for 30 min with PE-conjugated
streptavidin at 4 °C, washed again, and resuspended in 0.4 ml of
sorting buffer plus 2% paraformaldehyde. T lymphocytes were gated by
forward scatter and side scatter parameters, and 10,000 cells
were analyzed on a fluorescence-activated cell sorter Xcalibur system
using Cell Quest software. For irTS inhibition assay, biotin-conjugated irTS was preincubated with 2-3- or 2-6-SL in a range of 0-1 mM for 30 min at 4 °C.
ELISA Analysis of irTS Binding to Sialic Acid-containing
Molecules--
Analysis of irTS binding to sialic acid-containing
molecules was done by ELISA (24). Wells in microtiter plates were
coated overnight at 4 °C with a monoclonal antibody against the TS
repeats (25) (500 ng/well) in 50 mM carbonate/bicarbonate
buffer, pH 9.5. The plates were washed with ELISA buffer (3% bovine
serum albumin in PBS, pH 7.4) and incubated overnight at 4 °C with
irTS (500 ng/well) in the same buffer. Plates were blocked with ELISA buffer containing Triton X-100 1% for 1 h at room temperature and
subsequently washed. Wells were then incubated with biotin-conjugated PAA probes substituted with sialylated glycans at a final concentration of 5.0 µg/well or a range between 0.25 and 10.0 µg/well for 2 h at room temperature. Following washing, wells were incubated for
1 h at room temperature with peroxidase-conjugated streptavidin, diluted (1:500) in blocking buffer, and developed with the
2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) diamonium
substrate system (100 µl/well). The plates were read at 405 nm in an
automatic microplate reader (Bio-Tek Instruments). Control wells
received a polyclonal antibody against TS catalytic domain (anti-TS)
(25) (500 ng/well) for 1 h. Both mono- and polyclonal antibodies
were generously supplied by Dr. Maurício M. Rodrigues from the
Universidade Federal de São Paulo, São Paulo, Brasil.
Mild Periodate Treatment of Sialylated PAA Probes--
The
sialylated PAA probes (40 µg) were oxidized with 200 µl of 2 mM NaIO4 in PBS for 30 min at 4 °C in the
dark and reduced with 200 µl of 10 mM NaBH4
in PBS saline for 1 h at 4 °C (24). The products were diluted
5× with ELISA buffer and used in the assay. For sham treatment, 2 mM NaIO4 and 10 mM
NaBH4 were mixed for 1 h at 4 °C and diluted with
ELISA buffer, and sialylated PAA probes were added to this mixture just
before use in the assay.
Carboxyl Reduction of Sialylated PAA Probes by Iodoethano and
Sodium Borohydride Treatment--
Sialylated PAA probes were
carboxyl-reduced with sodium borohydride treatment after esterification
with iodoethane (24). Briefly, 100 µg of lyophilized sialylated PAA
probes was solubilized in 350 µl of dimethyl sulfoxide, esterified
with 35 µl of CH3CH2I for 1 h at room
temperature, and then reduced by addition of 1.115 ml of PBS buffer
containing 10 mM NaBH4. The reaction products were diluted 4× with ELISA buffer and directly used in the assay. For
sham treatment, the same procedures were performed without adding
CH3CH2I.
Analysis of Relative Biotinylation Level of Sialylated PAA
Probes--
Microtiter plates were coated with biotinylated PAA probes
(200 ng/well) overnight at 4 °C in 50 mM
carbonate/bicarbonate buffer, pH 9.5. After blocking with ELISA buffer
and subsequent washing, the wells were incubated for 1 h at room
temperature with peroxidase-conjugated streptavidin diluted 1:500 times
and developed with 100 µl/well
2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diamonium
substrate system. The plates were read at 405 nm in an automated
microplate reader.
NMR Experiments--
2-3-SL, 2-6-SL, SLeX, or methyl
-mannoside was dissolved in deuterated PBS, pH 7.6 (not corrected
for isotope effects). irTS solution in 20 mM Tris-HCl was
exchanged with deuterated PBS by gel filtration on a G25 column. 20 µl of a stock solution containing 10 mg/ml of irTS was added to a
solution of sialyl glycoside (2 mM final concentration),
and the total volume was adjusted to 500 µl. NMR spectra were
obtained at a probe temperature of 20 °C on a Bruker DMX 600 equipped with a 5-mm self-shielded gradient triple resonance probe or
on a Bruker DRX 600 with a 5-mm triple resonance probe.
One-dimensional Saturation Transfer Difference (One-dimensional
STD)--
One-dimensional STD experiments were performed by low
power presaturation of the methyl region of the protein during the 2-s relaxation delay. The pulse scheme was as follows: relaxation delay
with or without presaturation of the protein resonances, 90 degrees
pulse, and acquisition of 256 scans (16,000 points for 10 ppm of
spectral width). The data were obtained with interleaved acquisition of
on-resonanse and control spectra to minimize the effects of temperature
and magnet instability.
Saturation Transfer Difference--
Total Correlation
Spectroscopy (STD-TOCSY) spectra were recorded with a mixing time of 66 ms, 32 scans per t1 increment. 200 t1 increments were collected in an interlaced
mode with presaturation on or off for 2 s. Prior to subtraction,
both spectra were processed and phased identically. The acquisition
time for the two-dimensional experiments were typically 16 h. The
spectra were multiplied with a square cosine bell function in both
dimensions and zero-filled two times. All spectra were referenced
relative to
trimethyl-silyl-2,2',3,3'-d4-propionic acid-sodium salt ( = 0.0 ppm).
 |
RESULTS |
irTS Binds CD43 on T Cells--
We recently demonstrated that irTS
from T. cruzi binds CD4+ T cells and that this
binding is abrogated by prior treatment with anti-CD43 S7 mAb (18). To
prove that CD43 is the counterreceptor for TS on CD4+ T
cells, we investigated the interaction between irTS and the leukosialin
(CD43), using splenic CD4+ T cells from CD43-deficient mice
(CD43 / ). As compared with wild type, CD4+ T
cells from CD43 / mice failed to bind either anti-CD43
mAb S7 (Fig. 1A) or
biotin-conjugated irTS (Fig. 1B). To confirm that CD43 is
the counterreceptor for irTS, CD4+ T cell extracts from
wild-type and CD43 / mice were immunoprecipitated with
biotin-conjugated irTS or with anti-CD43 mAb S7. Precipitates were
immunoblotted and revealed with anti-CD43 mAb S7 (Fig. 1C).
Remarkably, both irTS and anti-CD43 mAb S7 immunoprecipitated the same
115-kDa protein band expected for CD43 (19). However, this protein was
absent when CD4+ T cells from CD43 / mice
were submitted to the same treatment (Fig. 1C). These
results indicate that CD43 expression is required for irTS binding on T
cells, showing that soluble irTS physically interacts with CD43.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 1.
CD43 is the counterreceptor for irTS on T
cells. Correlation between CD43 expression and irTS binding on T
cells was analyzed by FCM. Naive splenic T cells from wild-type
(bold line) or CD43 / mice (thin
line) were stained with fluorescein isothiocyanate-labeled
anti-CD43 mAb S7 (A) or biotin-labeled irTS followed by
PE-streptavidin (B). The incubation procedures were as
described under "Experimental Procedures." As shown in
C, CD4+ T cell extracts from wild-type
(WT) or CD43 / mice were immunoprecipitated
with anti-CD43 mAb S7 (lane 1) or biotin-labeled irTS
(lane 2). The precipitates were resolved by SDS-PAGE,
electro-transferred, and revealed with anti-CD43 mAb S7 by enhanced
chemiluminescence.
|
|
2-3-linked Sialic Acid Is the Epitope for irTS on T
Cells--
CD43 is the most abundant glycoprotein bearing 2-3- and
2-6-linked sialic acids expressed on the surface of T cells (26). To investigate whether sialic acid is the epitope for irTS, T cells
were treated with C. perfringens sialidase, and the binding of biotinylated irTS was tested. Fig.
2A (a) shows that
irTS binds to T cells, and this binding is abrogated by sialidase
treatment (Fig. 2A (b)). irTS binding was
reconstituted with high intensity by resialylation of T cells with rTS
in the presence of 2-3-SL as donor substrate (Fig. 2A
(c)). Since TS catalyzes the transfer of sialic acid
residues from NeuAc 2-3Galp 1-x-containing
donors and attaches them in an 2-3 linkage to terminal
Galp-containing molecules (9), our results clearly show
that irTS binds 2-3-linked sialic acid. The specificity of the
interaction of irTS with 2-3-linked sialic acid was confirmed by
inhibition studies using 2-3- (Fig. 2A (d))
or 2-6-SL (Fig. 2A (e)). As shown in Fig.
2A (d), binding of irTS to T cells was abrogated
by the previous incubation of irTS with 2-3-SL but not with
2-6-SL (Fig. 2A (e)). These results are
consistent with the irTS bright pattern of staining observed after
resialylation of T cells by rTS (Fig. 2A (c))
since these cells now must bear almost exclusively 2-3-linked
sialic acid. In addition, previous treatment of irTS with 2-3-SL
completely disrupt irTS binding to resialylated T cells (Fig.
2A (f)). This inhibition was
dose-dependent and had an IC50 of 0.49 mM (Fig. 2B).

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 2.
irTS binding to T cells relies on
2-3-linked sialic acid. As shown in
A, binding of biotin-labeled irTS to T cells (a)
is eliminated by previous C. perfringens sialidase treatment
(b). irTS binding is reconstituted with high intensity by
previous resialylation of T cells with rTS (c). Binding of
biotin-labeled irTS is abrogated by preincubation of irTS with soluble
2-3-SL (d) but not with soluble 2-6-SL
(e). Soluble 2-3-SL abrogates iTS binding to
resialylated T cells (f). Untreated, desialylated and
resialylated T cells, obtained as described under "Experimental
Procedures," were incubated with biotin-conjugated irTS, stained with
PE-conjugated streptavidin, and analyzed by FCM. B,
concentration-dependent inhibition of irTS binding by
2-3-SL (squares) and 2-6-SL
(triangles).
|
|
Binding Preferences of irTS for Sialic Acid-containing
Molecules--
The irTS preference for 2-3-linked sialic acid was
further investigated using sialylated PAA probes. Fig.
3 shows that irTS strongly binds to
2-3-linked sialic acid. Binding was dependent on the concentration
of 2-3-SL-PAA, being maximal at 10 µg/ml, and relies on the
carboxylate group of sialic acid since irTS binding is abrogated after
carboxyl reduction (Fig. 3). Furthermore, when 2-6-SL- or SLeX-PAA
probes were used as ligands, low level binding or no binding to irTS
was observed, respectively (Fig. 4).

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 3.
Involvement of the carboxyl group of sialic
acid in irTS binding to 2-3-SL. irTS
binds to 2-3-SL-PAA (squares) and irTS binding is
drastically reduced after carboxyl reduction of 2-3-SL-PAA
(triangles). Binding was assayed by ELISA as described under
"Experimental Procedures." Data show the mean ± S.D. of
duplicates.
|
|

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 4.
Binding of irTS to sialylated PAA
probes. Sialylated PAA probes conjugated to 2-3-SL,
2-6-SL, or SleX were either untreated or treated with periodate and
added to immobilized irTS in the presence or absence of anti-TS
(antibodies against the TS catalytic site). Binding was tested by ELISA
as described under "Experimental Procedures." Data show the
mean ± S.D. of duplicates. Black column, PAA
sham-treated; White column, PAA mild periodate-treated;
Gray column, PAA + anti-TS.
|
|
Periodate treatment of sialylated PAA probes did not reduce irTS
binding (Fig. 4), demonstrating that the sialic acid side chain is not
required for irTS recognition. Taken together, these data suggest that
irTS displays a binding site that recognizes 2-3-linked sialic acid
and its 7-carbon analog and that this binding can be abolished by
either fucosylation or carboxyl reduction. Interactions of irTS with
all sialylated PAA probes were inhibited in the presence of a
polyclonal antibody directed against epitopes present in the catalytic
domain of the active TS (Fig. 4) (25).
NMR Study of irTS Binding to Sialic Acid-containing
Molecules--
To better understand the binding specificity observed
for irTS, NMR spectroscopy studies were employed. Saturation transfer difference (STD) experiments were used to verify soluble 2-3-SL interaction with irTS. The binding assay was done in the presence of
the methyl -mannoside, used as negative control. Fig.
5 shows the one-dimensional STD
experiment of irTS in the presence of 2-3-SL and methyl
-mannoside in D2O PBS, pH 7.6, at 20 °C. Binding of
2-3-SL can be followed by measuring the signal at 2.050 ppm assigned to the 5NAc protons of N-acetylneuraminic acid
(NeuAc) (27) and by the NeuAc H3 equatorial (eq) and axial (ax)
resonances at 2.727 and 1.812 ppm, respectively. Binding of methy
-mannoside would be detected by observation of the H1 and methyl
protons at 4.775 and 3.405 ppm, respectively, in the STD spectrum. The subtraction of the spectrum in which protein resonance was presaturated (0.5 ppm) (Fig. 5B) from the reference spectrum without
protein saturation (Fig. 5A) reveals the resonances at
2.727, 2.050, and 1.812 ppm (Fig. 5C) of NeuAc from
2-3-SL ligand involved in the binding to the protein. No signals
arising from methyl -mannoside were observed, showing that
2-3-SL binds to irTS in a specific interaction.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 5.
NMR spectroscopy of
2-3-SL bound to irTS. One-dimensional STD-NMR
spectroscopy of irTS in the presence of 2-3-SL (structure shown)
and methyl -mannoside in PBS-D2O, pH 7.6, 20 °C.
A, without protein saturation; B, with protein
saturation; C, difference spectrum of spectra from
panels A and B. Data were obtained with
interleaved acquisition of experimental and control spectra (16 × 16 scans), as described under "Experimental Procedures."
|
|
irTS interaction with 2-3-SL was further verified by
two-dimensional NMR experiments, which show in detail the key
structural elements of 2-3-SL involved in binding to irTS. A
reference TOCSY spectrum of irTS in the presence of 2-3-SL and
methyl -mannoside was recorded without protein presaturation and
with protein presaturation (0.5 ppm) (Fig.
6A). In the STD-TOCSY obtained
(Fig. 6B), the on-diagonal cross-peaks identify hydrogens in
close proximity with the protein in the complex. It is evident that
2-3-SL binds to irTS. As the relative signal intensities on the STD
spectrum correlate with the proximity to the protein, we can conclude
that NAc and the H3ax protons from the NeuAc are in close contact with irTS. In the STD-TOCSY spectrum, off-diagonal cross-peaks help identify
key hydrogens involved in binding. It is clear that the H3eq, H4, and
H5 from the NeuAc residue and the H1, H3 and H4 from the
Galp ring also interact with the irTS as they receive saturation from the protein (Fig. 6B). The H1 and H2 peaks
from the -anomer of Glcp are low in intensity, indicating
a loose contact with the irTS binding site. Cross-peaks arising from
-Glcp or from methyl -mannoside were not detected
(Fig. 6B). Binding of irTS to 2-6-linked sialic acid was
also investigated using STD. The STD-TOCSY spectrum obtained from
2-6-SL in the presence of irTS (Fig.
7) shows cross-peaks in which only NAc
(2.039 ppm), H3ax (1.755 ppm), and H3eq (2.721 ppm) from NeuAc
residue receive saturation from the protein. No signals emerging from
Galp or Glcp are visible. These results
indicate that irTS binds only to the sialic acid ring of 2-6-SL,
consistent with an improper positioning of the entire molecule in the
irTS binding site. Furthermore, in agreement with the experiments using
the SLeX-PAA probe (Fig. 4), STD-NMR does not show any binding between
irTS and soluble SLeX (data not shown).

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 6.
STD-TOCSY 2-3-SL
bound to irTS. A, reference TOCSY spectrum of irTS in
the presence of 2-3-SL and methyl -mannoside. B,
STD-TOCSY spectrum. Spectra were recorded in PBS-D2O, pH
7.6, 20 °C with a mixing time of 66 ms, 32 scans per
t1 increment. 200 t1
increments were collected in an interlaced mode for on or off
presaturation, as described under "Experimental Procedures."
|
|

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 7.
STD-TOCSY 2-6-SL
bound to irTS. STD-TOCSY of irTS in the presence of 2-6-SL in
PBS-D2O, pH 7.6, 20 °C with a mixing time of 66 ms, 32 scans per t1 increment. 200 t1 increments were collected in an interlaced
mode for on or off presaturation, as described under "Experimental
Procedures."
|
|
 |
DISCUSSION |
T. cruzi presents in its genome hundreds of genes
encoding a family of TS molecules and sialic acid acceptor
glycoproteins. Combined, the molecules expressed by both sets of genes
are likely to cover most of the parasite surface (13), warranting a
parasite-host interface. Around 140 genes encode for the TS family,
comprising enzymatically active as well as inactive members (10, 28, 29). Although no function has been assigned to the inactive TS, genes
coding for inactive members are present in a similar number in the
parasite genome as in those encoding active TS (12). In the present
work, we show for the first time that irTS can interact with host T
cells. Using wild-type and CD43 / mice and a combination
of FCM and immunoprecipitation techniques, we identified the sialomucin
CD43 as the counterreceptor for irTS on the T cell surface.
Furthermore, using biochemical, immunological, and spectroscopic
approaches, we directly demonstrate that irTS binds to 2-3-linked
sialic acid.
CD43, or leukosialin, is an abundant mucin expressed on T lymphocytes
and other bone marrow-derived cells with ubiquitous physiological roles
in cell-to-cell interactions. It is highly glycosylated with 80-90
O-linked glycosylation sites (26, 30). High surface density,
pronounced length of protruding molecules, and abundance of sialic acid
residues (26) make CD43 a candidate receptor for T. cruzi TS
on CD4+ T cells. Natural ligands for CD43 include
ICAM-1 (31), galectin-1 (32), class I major histocompatibility complex
(33), E-selectin (34), and a macrophage sialoadhesin (35). Our studies
indicate that TS is a parasite ligand for CD43 on CD4+ T
cells. Furthermore, soluble active and inactive TS costimulate CD4+ T cell activation through CD43 engagement, being a
candidate molecule for induction of immunopathology in T. cruzi infection (18). CD43 is a known receptor for other
pathogen-associated molecules. CD43 is a neutrophil receptor for
influenza A hemagglutinin (36), responsible in part for neutrophil
deactivation observed during infection (37). Macrophage invasion by
Mycobacterium also requires the extracellular domain of CD43
(38). Since the immunopathology of T. cruzi infection
involves multiple host cell types (16), binding of irTS to other
myeloid cells expressing CD43, such as macrophages, neutrophils, and
dendritric cells, should be investigated.
CD43 expressed on resting T lymphocytes is highly sialylated and
carries the tetrasaccharide core
NeuAc 2-3Gal 1-3(NeuAc)GalNAc 1-Ser/Thr (39). We therefore,
tested the hypothesis that sialic acid is the epitope for irTS binding
on CD43. Our results demonstrated that 2-3-linked sialic acid is
the epitope for irTS binding on CD43 and that irTS recognizes its
ligand with similar specificity to that described for active TS (9).
Thus, irTS showed a preferential binding for 2-3-linked sialic acid
and for its C7 derivative obtained by truncation of the sialic acid
side chain after mild periodate oxidation (1, 9). Another
characteristic shared by both proteins is that active and inactive TS
are unable to recognize 2-3-sialyllactosamine bearing a fucose
residue, forming the SLeX epitope (9). We converted the carboxyl group
of sialic acid into an alcohol on the 2-3-SL-PAA probe to explore
its role on irTS binding. Our results show that the sialic acid
carboxyl group is essential for irTS binding. It is known that the
catalytic domain of TS contains three arginine residues that bind the
carboxyl group of sialic acid (3, 5). Therefore, the sialic acid binding site found in irTS might be the same present in active TS.
Consistent with these findings, an antibody directed against an epitope
present in the catalytic domain of active TS (25) was able to inhibit
irTS binding to sialic acid-containing PAA probes.
NMR spectroscopy was used to investigate a physical interaction between
irTS and sialic acid-containing molecules. NMR spectroscopy has been a
valuable tool in studying interactions between ligands and receptors
and provides detailed information about binding site and binding
conformations in a noninvasive manner (40). The STD NMR technique has
been used to distinguish those molecules that bind to a macromolecule
from nonbinding compounds (41-44). This technique relies on
selective saturation of resonances arising from the receptor protein
that spin-diffuses efficiently over the entire protein and consequently
is transferred to the bound ligand. This disturbance on spin states in
the population is carried by the ligand when released and detected as a
reduction in the intensity of resonances in the free ligand. The
relative intensity of the signals present in the STD spectrum
identifies those nuclei closest to the protein in the binding site,
permitting a detailed mapping of the interactions involved (42, 44,
45). Using one-dimensional and two-dimensional STD experiments, we
demonstrated that 2-3-SL ligand binds to irTS. From our results, it
is possible to map the structural regions of 2-3-SL most involved
in binding to irTS. The 5NAc, H3eq, H3ax, H4, and H5 of the NeuAc
residue and the H1, H3, and H4 from Galp are in contact
with irTS, whereas the Glcp residue is not involved in
the binding to the protein. No interaction between the glycerol side
chain and irTS was found, reinforcing our finding that mild periodate
treatment does not impair irTS recognition. Furthermore, only NAc,
H3ax, and H3eq from the NeuAc residue of 2-6-SL receive saturation
from irTS, indicating that the loose binding of 2-6-SL to irTS is
due to an incorrect positioning of the entire molecule in the TS
binding pocket. Recently, the involvement of the Trp312 in
the T. cruzi TS activity was demonstrated (46). The single mutation Trp312 Ala rendered the TS capable of
hydrolyzing both 2-3- and 2-6-linked sialylmolecules. Here we
verified that the 2-6-SL does not bind correctly to the irTS
pocket, suggesting that Trp312 prevents 2-6-linked
sialic acid binding and that a proper positioning of the sialoside is
necessary in active TS for the transfer reaction to take place.
This is the first time that binding of sialic acid-containing molecules
by a catalytically inactive member of the T. cruzi TS family
has been unambiguously proven. Our results show that irTS conserves its
binding site for sialic acid despite its lack of enzymatic activity. It
has been suggested that the Tyr342 His mutation
abrogates the catalytic activity due to the role of Tyr342
in stabilizing the carbonium ion transition state intermediate (4, 5).
We now demonstrate that this site mutation does not abolish binding to
sialic acid donor molecules and confirm the prediction that loss of the
enzymatic activity might generate lectin-like molecules from TS (12).
Molecules having mutually exclusive glycosidase or lectin activities
have been described in mammalian cells, in a family of chitinases.
Although some of their members are glycosylhydrolases, others are
chitin-specific lectins that lack enzymatic activity (47). Another
example is a disulfide-bonded dimer of the Golgi-galactoside
2-6-sialyltransferase that is catalytically inactive and retains
the ability to bind galactose (48). In addition, site-directed
mutagenesis of Newcastle disease virus hemagglutinin-neuraminidase
found functional and topological relationships between the
neuraminidase and receptor binding activities of hemagglutinin
(49).
In summary, we demonstrated that CD43 is the counterreceptor for irTS
on CD4+ T cells. Using different approaches, we directly
demonstrated that irTS is a sialic acid-binding protein. Taken
together, our results suggest that inactive molecules of the
trans-sialidase family still retain sialic acid binding
activity and could behave as lectins that bind and transmit signals to
cells of the host immune system during T. cruzi infection.
 |
ACKNOWLEDGEMENTS |
We thank Dr. A. C. C. Frasch from
Universidad Nacional de General San Martin, Argentina, for the gift of
both rTS and irTS-expressing plasmid, Dr. M. M. Rodrigues and Dr.
M. Correa from Universidade Federal de São Paulo, Brasil, for the
TS antibodies, and for the CD43 / and wild-type
mice, respectively. We also thank Dr. G. Lippens from Laboratoire de
RMN Synthese, Structure et Fonction des Biomolecules, Institut Pasteur,
Lille, France, and Centro Nacional de Ressonância Magnética
Nuclear, UFRJ, Brasil, for the NMR facilities.
 |
FOOTNOTES |
*
This work was supported by grants from Conselho Nacional de
Desenvolvimento Científico e Tecnológico (Programa
de Apoio ao Desenvolvimento Científico e Tecnológico,
Programa Núcleo de Excelência), Fundação Carlos
Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro,
Fundação Universitaria José
Bonifácio-Universidade Federal do Rio de Janeiro, and
Coordenação de Aperfeiçoamento de Pessoal de
Nível Superior-Comité Français
D'Évaluation De La Coopération Universitaire Avec de
Brésil.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
A recipient of a post-doctoral fellowship from Bourse
Lavoisier du Ministère des Affaires Etrangèrés, France.
**
Howard Hughes International Research Scholars.

To whom correspondence should be addressed. Tel.:
55-21-2562-6646; Fax: 55-21-22808193; E-mail:
luciamp@biof.ufrj.br.
Published, JBC Papers in Press, September 16, 2002, DOI 10.1074/jbc.M203185200
 |
ABBREVIATIONS |
The abbreviations used are:
TS, trans-sialidase;
iTS, inactive trans-sialidase;
irTS, recombinant inactive trans-sialidase;
rTS, recombinant
active trans-sialidase;
2-3-SL, 2-3-sialyllactose;
2-6-SL, 2-6-sialyllactose;
Galp, -galactopyranose;
Fuc, fucose;
SLeX, NeuAc 2-3Gal 1-3(Fuc 1-4)-GlcNAc;
PAA, polyacrylamide;
PE, phycoerythrin;
PBS, phosphate-buffered saline;
ELISA, enzyme-linked
immunosorbent assay;
FCM, flow cytometry;
STD, saturation transfer
difference;
TOCSY, total correlation spectroscopy;
mAb, monoclonal
antibody.
 |
REFERENCES |
| 1.
|
Previato, J. O.,
Andrade, A. F. B.,
Pessolani, M. C. V.,
and Mendonça-Previato, L.
(1985)
Mol. Biochem. Parasitol.
16,
85-96[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Schenkman, S.,
Jiang, M. S.,
Hart, G. W.,
and Nussenzweig, V.
(1991)
Cell
65,
1117-1125[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Roggentin, P.,
Rothe, B.,
Kaper, J. B.,
Galen, J.,
Lawrisuk, L.,
Vimr, E. R.,
and Schauer, R.
(1989)
Glycoconj. J.
6,
349-353[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Todeschini, A. R.,
Mendonça-Previato, L.,
Previato, J. O.,
Varki, A.,
and van Halbeek, H.
(2000)
Glycobiology
10,
213-221[Abstract/Free Full Text]
|
| 5.
|
Buschiazzo, A.,
Tavares, G. A.,
Campetella, O.,
Spinelli, S.,
Cremona, M. L.,
Paris, G.,
Amaya, M. F.,
Frasch, A. C.,
and Alzari, P. M.
(2000)
EMBO J.
19,
16-24[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Crennell, S. J.,
Garman, E. F.,
Laver, W. G.,
Vimr, E. R.,
and Taylor, G. L.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
9852-9856[Abstract/Free Full Text]
|
| 7.
|
Crennell, S.,
Garman, E.,
Laver, G.,
Vimr, E.,
and Taylor, G.
(1994)
Structure
2,
535-544[Medline]
[Order article via Infotrieve]
|
| 8.
|
Garskell, A.,
Crennell, S. J.,
and Taylor, G.
(1995)
Structure
15,
1197-1205
|
| 9.
|
Vandekerckhove, F.,
Schenkman, S.,
Pontes de Carvalho, L.,
Tomlinson, S.,
Kiso, M.,
Yoshida, M.,
Hasegawa, A.,
and Nussenzweig, V.
(1992)
Glycobiology
2,
541-548[Abstract/Free Full Text]
|
| 10.
|
Uemura, H.,
Schenkman, S.,
Nussenzweig, V.,
and Eichinger, D.
(1992)
EMBO J.
11,
3837-3844[Medline]
[Order article via Infotrieve]
|
| 11.
|
Cremona, M. L.,
Sanchez, D. O.,
Frasch, A. C. C.,
and Campetella, O.
(1995)
Gene (Amst.)
160,
123-128[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Cremona, M. L.,
Campetella, O.,
Sanchez, D. O.,
and Frasch, A. C. C.
(1999)
Glycobiology
9,
581-588[Abstract/Free Full Text]
|
| 13.
|
Frasch, A. C.
(2000)
Parasitol. Today
16,
282-286[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Burleigh, B. A.,
and Andrews, N. W.
(1995)
Annu. Rev. Microbiol.
49,
175-200[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Chuenkova, M.,
and Pereira, M. E.
(1995)
J. Exp. Med.
181,
1693-1703[Abstract/Free Full Text]
|
| 16.
|
DosReis, G. A.
(1997)
Parasitol. Today
13,
335-342[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Hunter, C. A,
Ellis-Neys, L. A.,
Slifer, T.,
Kanaly, S.,
Gruning, G.,
Fort, M.,
Rennick, D.,
and Araújo, F. G.
(1997)
J. Immunol.
158,
3311-3316[Abstract]
|
| 18.
|
Todeschini, A. R.,
Nunes, M. P.,
Pires, R. S.,
Lopes, M. F.,
Previato, J. O.,
Mendonça-Previato, L.,
and DosReis, G. A.
(2002)
J. Immunol.
168,
5192-5198[Abstract/Free Full Text]
|
| 19.
|
Jones, A. T.,
Federsppiel, B.,
Ellies, L. G.,
Williams, M. J.,
Burgener, R.,
Duronio, V.,
Smith, C. A.,
Takei, F.,
and Ziltener, H. J.
(1994)
J. Immunol.
153,
3426-3439[Abstract]
|
| 20.
|
Buschiazzo, A.,
Frasch, A. C.,
and Campetella, O.
(1996)
Cell. Mol. Biol. (Oxf.)
42,
703-710[Medline]
[Order article via Infotrieve]
|
| 21.
|
Harlow, E.,
and Lane, D.
(1988)
Antibodies: a Laboratory Manual
, pp. 340-354, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 22.
|
Manjunath, N.,
Correa, M.,
Ardman, M.,
and Ardman, B.
(1995)
Nature
377,
535-538[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Lopes, M. F.,
Veiga, V. F.,
Santos, A. R.,
Fonseca, M. E. F.,
and Dos Reis, G. A.
(1995)
J. Immunol.
154,
744-752[Abstract]
|
| 24.
|
Brinkman-van der Linden, E. C. M.,
and Varki, A.
(2000)
J. Biol. Chem.
275,
8625-8632[Abstract/Free Full Text]
|
| 25.
|
Costa, F.,
Franchin, G.,
Pereira-Chioccola, V. L.,
Ribeirão, M.,
Schenkman, S.,
and Rodrigues, M. M.
(1998)
Vaccine
16,
768-774[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Ostberg, J. R.,
Barth, R. K.,
and Frelinger, J. G.
(1998)
Immunol. Today
19,
546-550[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Reuter, G.,
and Schauer, R.
(1994)
Methods Enzymol.
230,
168-199[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Pollevick, G. D.,
Affranchino, J. L.,
Frasch, A. C.,
and Sanchez, D. O.
(1991)
Mol. Biochem. Parasitol.
47,
247-250[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Parodi, A. J.,
Pollevick, G. D.,
Mautner, M.,
Buschiazzo, A.,
Sanchez, D. O.,
and Frasch, A. C.
(1992)
EMBO J.
11,
1705-1710[Medline]
[Order article via Infotrieve]
|
| 30.
|
Sabri, S.,
Soler, M.,
Foa, C.,
Pierres, A.,
Benoliel, A.,
and Bongrand, P.
(2000)
J. Cell Sci.
113,
1589-1600[Abstract]
|
| 31.
|
Rosenstein, Y.,
Park, J. K.,
Hahn, W. C.,
Rosen, F. S.,
Bierer, B. E.,
and Burakoff, S. J.
(1991)
Nature
354,
233-235[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Baum, L. G.,
Derbin, K.,
Perillo, N. L., Wu, T.,
Pang, M.,
and Uittenbogaart, C.
(1996)
J. Biol. Chem.
271,
10793-17999[Abstract/Free Full Text]
|
| 33.
|
Stockl, J.,
Majdic, O.,
Kohl, P.,
Pickl, W.,
Menzel, J. E.,
and Knapp, W.
(1996)
J. Exp. Med.
184,
1769-1779[Abstract/Free Full Text]
|
| 34.
|
Sawada, R.,
Tsuboi, S.,
and Fukuda, M.
(1994)
J. Biol. Chem.
269,
1425-1431[Abstract/Free Full Text]
|
| 35.
|
van den Berg, T. K.,
Nath, D.,
Ziltener, H. J.,
Vestweber, D.,
Fukuda, M.,
van Die, I.,
and Crocker, P. R.
(2001)
J. Immunol.
166,
3637-3640[Abstract/Free Full Text]
|
| 36.
|
Rothwell, S. W.,
and Wright, D. G.
(1994)
J. Immunol.
152,
2358-2367[Abstract]
|
| 37.
|
Abramson, J. S.,
and Hudnor, H. R.
(1995)
Blood
85,
1615-1619[Abstract/Free Full Text]
|
| 38.
|
Fratazzi, C.,
Manjunath, N.,
Arbeit, R. D.,
Carini, C.,
Gerken, T. A.,
Ardman, B.,
Remold-O'Donnell, E.,
and Remold, H. G.
(2000)
J. Exp. Med.
192,
183-192[Abstract/Free Full Text]
|
| 39.
|
Carlsson, S. R.,
Sasaki, H.,
and Fukuda, M.
(1986)
J. Biol. Chem.
261,
12787-12795[Abstract/Free Full Text]
|
| 40.
|
Diercks, T.,
Coles, M.,
and Kessler, H.
(2001)
Curr. Opin. Chem. Biol.
5,
285-291[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Mayer, M.,
and Meyer, B.
(1999)
Angew. Chem. Int. Ed. Engl.
38,
1784-1788[CrossRef]
|
| 42.
|
Mayer, M.,
and Meyer, B.
(2001)
J. Am. Chem. Soc.
123,
6108-6117[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Vogtherr, M.,
and Peters, T.
(2000)
J. Am. Chem. Soc.
122,
6093-6099[CrossRef]
|
| 44.
|
Möller, H.,
Serttas, N.,
Paulsen, H.,
Burchell, J. M.,
Taylor-Papadimitriou, J.,
and Meyer, B.
(2002)
Eur. J. Biochem.
269,
1444-1455[Medline]
[Order article via Infotrieve]
|
| 45.
|
Maaheimo, H.,
Kosma, P.,
Brade, L.,
Brade, H.,
and Peters, T.
(2000)
Biochemistry
39,
12778-12788[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Paris, G.,
Cremona, M. L.,
Amaya, M. F.,
Buschiazzo, A.,
Giambiagi, S.,
Frasch, A. C. C.,
and Alzari, P. M.
(2001)
Glycobiology
11,
305-311[Abstract/Free Full Text]
|
| 47.
|
Renkema, G. H.,
Boot, R. G., Au, F. L.,
Donker-Koopman, W. E.,
Strijland, A.,
Muijsers, A. O.,
Hrebicek, M.,
and Aerts, J. M.
(1998)
Eur. J. Biochem.
251,
504-509[Medline]
[Order article via Infotrieve]
|
| 48.
|
Ma, J.,
and Colley, K. J. A
(1996)
J. Biol. Chem.
271,
7758-7766[Abstract/Free Full Text]
|
| 49.
|
Iorio, R. M.,
Field, G. M.,
Sauvron, J. M.,
Mirza, A. M.,
Deng, R.,
Mahon, P. J.,
and Langedijk, J. P.
(2001)
J. Virol.
75,
1918-1927[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. L DeMarco and R. J Woods
Structural glycobiology: A game of snakes and ladders
Glycobiology,
June 1, 2008;
18(6):
426 - 440.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Mucci, E. Mocetti, M. S. Leguizamon, and O. Campetella
A Sexual Dimorphism in Intrathymic Sialylation Survey Is Revealed by the trans-Sialidase from Trypanosoma cruzi
J. Immunol.,
April 15, 2005;
174(8):
4545 - 4550.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Woronowicz, K. De Vusser, W. Laroy, R. Contreras, S. O. Meakin, G. M. Ross, and M. R. Szewczuk
Trypanosome trans-sialidase targets TrkA tyrosine kinase receptor and induces receptor internalization and activation
Glycobiology,
November 1, 2004;
14(11):
987 - 998.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Haselhorst, J. C. Wilson, A. Liakatos, M. J. Kiefel, J. C. Dyason, and M. von Itzstein
NMR spectroscopic and molecular modeling investigations of the trans-sialidase from Trypanosoma cruzi
Glycobiology,
October 1, 2004;
14(10):
895 - 907.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. R. Todeschini, W. B. Dias, M. F. Girard, J.-M. Wieruszeski, L. Mendonca-Previato, and J. O. Previato
Enzymatically Inactive trans-Sialidase from Trypanosoma cruzi Binds Sialyl and {beta}-Galactopyranosyl Residues in a Sequential Ordered Mechanism
J. Biol. Chem.,
February 13, 2004;
279(7):
5323 - 5328.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|